Evaluating in vivo effectiveness of sotrovimab for the treatment of Omicron subvariant BA.2 versus BA.1: a multicentre, retrospective cohort study

Evaluating in vivo effectiveness of sotrovimab for the treatment of Omicron subvariant BA.2 versus BA.1: a multicentre, retrospective cohort study

Abstract Background In vitro data suggested reduced neutralizing capacity of sotrovimab, a monoclonal antibody, against Omicron BA.2 subvariant. However, limited in vivo data exist regarding clinical effectiveness of sotrovimab for coronavirus disease 2019 (COVID-19) due to Omicron BA.2. Methods A m...

Full description

Bibliographic Details
Main Authors: Carson K. L. Lo, Calvin K. F. Lo, Adam S. Komorowski, Victor Leung, Nancy Matic, Susan McKenna, Santiago Perez-Patrigeon, Prameet M. Sheth, Christopher F. Lowe, Zain Chagla, Anthony D. Bai
Format: Article
Language:English
Published: BMC 2024-01-01
Series:BMC Research Notes
Subjects:
Sotrovimab
SARS-CoV-2
COVID-19
COVID-19 drug treatment
Omicron
BA.2 subvariant
Online Access:https://doi.org/10.1186/s13104-024-06695-x

Internet

https://doi.org/10.1186/s13104-024-06695-x

Similar Items